Genomes and Genes
Summary: A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
Publications305 found, 100 shown here
- Health-related quality of life in patients with pulmonary arterial hypertensionShirin Shafazand
The George Washington University, Washington Hospital Center, Washington, DC, USA
Chest 126:1452-9. 2004..This study describes HRQOL in a cohort of patients with PAH...
- Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertensionDavid M Smadja
Universite Paris Descartes, Paris, France
Angiogenesis 14:17-27. 2011..In the present study, objectives were to determine whether EPC may contribute to vasodilator treatment efficacy in PAH...
- High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapyM Ozkan
Departments of Pulmonary and Critical Care Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Lung 179:233-43. 2001..with PPH and secondary pulmonary hypertension (SPH) on various therapies, including the potent vasodilator epoprostenol (prostacyclin), compared with healthy controls...
- Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteriesBin Liu
Cardiovascular Research Center, Shantou University College of Medicine, 22 Xin Ling Road, Shantou, China 515041
Exp Physiol 97:277-89. 2012....
- Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trialVictor F Tapson
Division of Pulmonary and Critical Care Medicine, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
Chest 129:683-8. 2006Pulmonary arterial hypertension (PAH) is a life-threatening disease for which both continuous IV epoprostenol and continuous subcutaneous treprostinil have proven effective...
- Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinilR J Barst
Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
Eur Respir J 28:1195-203. 2006Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exercise capacity and haemodynamics in PAH, and increases survival in idiopathic PAH (IPAH)...
- Angiogenesis induced by CNS inflammation promotes neuronal remodeling through vessel-derived prostacyclinRieko Muramatsu
Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Nat Med 18:1658-64. 2012..These findings reveal an important function of angiogenesis in neuronal rewiring and suggest that prostacyclin is a promising molecule for enhancing functional recovery from CNS disease...
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trialVallerie V McLaughlin
University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
J Am Coll Cardiol 55:1915-22. 2010..This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil...
- Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscleS P Williams
Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Ohio
Am J Physiol 267:H796-803. 1994..0 and 2.3 microM, respectively. These results suggest that 1) PGI2 induces relaxation through a PGI2-PGE1 receptor, and 2) higher concentrations of PGI2 act at the TxA2-PGH2 receptor to decrease PGI2-induced relaxation...
- Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transferS K Shyue
Vascular Biology Program, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
Circulation 103:2090-5. 2001..Combined COX-1 and PGIS gene transfer has the potential for therapeutic augmentation of prostacyclin...
- Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoproteinDonghui Liu
The Institute of Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center, Haidian District, Beijing, China
Cardiovasc Hematol Disord Drug Targets 12:98-105. 2012....
- Induction of prostacyclin/PGI2 synthase expression after cerebral ischemia-reperfusionYao Ching Fang
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
J Cereb Blood Flow Metab 26:491-501. 2006..These findings indicate that PGIS protects the brain by enhancing PGI2 synthesis and creating a favorable PGI2/TXA2 ratio...
- Living with pulmonary artery hypertension: patients' experiencesMaureen P Flattery
Cardiopulmonary Transplant Program, Richmond, Virginia 23298, USA
Heart Lung 34:99-107. 2005..Little investigation has been done on the impact of living with PAH despite inferences that quality of life (QOL) improves...
- Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-mannerSilvia S Barbieri
Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milano, Italy
Circulation 126:1373-84. 2012..Selective inhibitors of cyclooxygenase (COX)-2 increase the risk of myocardial infarction and thrombotic events, but the responsible mechanisms are not fully understood...
- Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclinCristina Rodriguez
Centro de Investigacion Cardiovascular CSIC ICCC, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Thromb Haemost 101:665-73. 2009....
- Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertensionRoald J Roeleveld
Department of Pulmonology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
Chest 125:572-9. 2004To gain more knowledge of changes in main pulmonary artery flow and right ventricular mass and volumes in patients with pulmonary hypertension during epoprostenol therapy.
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survivalOlivier Sitbon
Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
J Am Coll Cardiol 40:780-8. 2002We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion.
- Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysemaYan Chen
First Department of Medicine, Shinshu University School of Medicine, 3 1 1 Asahi, Matsumoto 390 8621, Japan
Am J Physiol Lung Cell Mol Physiol 296:L648-56. 2009..BPS may potentially represent a new therapeutic option in the prevention of emphysema in humans in prospect...
- Updated evidence-based treatment algorithm in pulmonary arterial hypertensionRobyn J Barst
Columbia University, New York, New York 10583, USA
J Am Coll Cardiol 54:S78-84. 2009..Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO functional class IV patients...
- Peroxynitrite and vascular endothelial dysfunction in diabetes mellitusMing Hui Zou
Vascular Research Laboratory, Graduate School of Medicine, University of Tennessee, Knoxville, TN 37920, USA
Endothelium 11:89-97. 2004..The authors' studies indicate that in diabetes the synthetic enzymes of the two major endogenous vasodilators undergo oxidative inactivation by different mechanisms, which are, however, tightly interdependent...
- Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritisTetsuya Honda
Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606 8501, Japan
J Exp Med 203:325-35. 2006..Our results show significant roles of both PGI2-IP and PGE2-EP2/EP4 signaling in the development of CIA, and suggest that inhibition of PGE2 synthesis alone may not be sufficient for suppression of RA symptoms...
- Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trialJagdish Hiremath
Ruby Hall Clinic, Pune, India
J Heart Lung Transplant 29:137-49. 2010..Pulmonary arterial hypertension (PAH) remains a poorly understood and frequently lethal disease with few treatment options...
- Increased bone mass in adult prostacyclin-deficient miceChalida Nakalekha
Department of Cellular Physiological Chemistry, Tokyo Medical and Dental University, Bunkyo ku, Tokyo 113 8549, Japan
J Endocrinol 204:125-33. 2010..Our findings demonstrate for the first time that PGI(2) is involved in bone metabolism in vivo...
- COX-2 inhibitors and cardiovascular riskColin D Funk
Department of Biochemistry, Queen s University, Kingston, Ontario, Canada
J Cardiovasc Pharmacol 50:470-9. 2007..This review discusses the background to our current understanding of coxibs and provides further information relating to recent mechanistic insights into how COX-2 inhibition promotes cardiovascular risk...
- Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusionC Shane McSwain
Clinical Affairs, United Therapeutics Corporation, One Park Drive, 4th Floor, Research Triangle Park, NC 27709, USA
J Clin Pharmacol 48:19-25. 2008..941 (95% confidence interval: 0.809-1.073). This study supports previous findings of linearity at lower doses up to 15 ng/kg/min and demonstrates linearity at treprostinil doses up to 125 ng/kg/min...
- Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertensionMichael Zlupko
Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania School of Medicine, Penn Presbyterian Medical Center, Suite 120, 51 North 39th Street, Philadelphia, PA 19104, USA
Respir Med 102:1431-8. 2008..The Minnesota Living with Heart Failure questionnaire was recently adapted and validated for HRQOL measurement in PAH. We applied this pulmonary hypertension-specific version (MLHF-PH) to a larger population of PAH patients...
- An outcome study of severe traumatic head injury using the "Lund therapy" with low-dose prostacyclinS Naredi
Department of Anaesthesia and Intensive Care, Umea University Hospital, Sweden
Acta Anaesthesiol Scand 45:402-6. 2001..The present clinical outcome study aims at evaluating whether the previously obtained good outcome with the Lund therapy can be reproduced, and whether the addition of prostacyclin has any adverse side-effects...
- Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapiesWarren D Rosenblum
Division of Cardiology, Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
Cardiol Rev 18:58-63. 2010..Although much needs to be learned, this review will discuss our current knowledge, results of clinical trials, along with treatment options and emerging therapies available for the treatment of this disorder...
- Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonistsS Shinomiya
Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, 5 9 1 Shirokane, Minato ku, Tokyo 108 8641, Japan
Biochem Pharmacol 61:1153-60. 2001..Thus the results suggest that PGI(2) and PGE(2) generated simultaneously with cytokines by macrophages treated with zymosan may influence the cytokine production through IP, EP2, and EP4 receptors...
- Prostacyclin and its analogues in the treatment of pulmonary hypertensionHorst Olschewski
Medical Clinic II, Klinikstrasse 36, D 35392 Giessen, Germany
Pharmacol Ther 102:139-53. 2004..It remains to be determined which patients will profit most from which substance (or combination) and mode of application...
- Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin productionMonika Riederer
Institute of Molecular Biology and Biochemistry, University of Helsinki, Helsinki, Finland
J Lipid Res 51:2957-66. 2010....
- Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatchingJaou Chen Huang
Department of Obstetrics and Gynecology, University of Texas Health Science Center Houston, Houston, TX 77030, USA
Hum Reprod 19:2900-6. 2004..The role of prostaglandins (PGs) in embryo hatching remains controversial. In addition, there is no direct evidence that mouse embryos synthesize PGs...
- Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVFJ C Huang
Department of Obstetrics, Gynecology and Reproductive Services, The University of Texas Health Science Center, Houston, TX 77030, USA
Hum Reprod 22:807-14. 2007..The mechanism underlying the effects of PGI(2) is unclear. It has been reported that peroxisome proliferator-activated receptor delta (PPARdelta) mediates the effects of PGI(2) at the implantation sites...
- COX-2-derived prostacyclin confers atheroprotection on female miceKarine M Egan
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, PA 19104, USA
Science 306:1954-7. 2004..This suggests that chronic treatment of patients with selective inhibitors of COX-2 could undermine protection from cardiovascular disease in premenopausal females...
- PGI2 as a regulator of CD4+ subset differentiation and functionMadison G Boswell
Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
Prostaglandins Other Lipid Mediat 96:21-6. 2011..In contrast, PGI(2) seems to enhance Th17-favoring polarization conditions, resulting in Th17 cytokine production. Therefore, PGI(2) may either promote or inhibit individual CD4+ cell subsets and impact adaptive immune responses...
- Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trialGerald Simonneau
Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
Am J Respir Crit Care Med 165:800-4. 2002..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
- Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuliMercedes Camacho
Angiology, Vascular Biology, and Inflammation Laboratory, Institute of Biomedical Research IIB Sant Pau, Barcelona, Spain
J Lipid Res 52:720-31. 2011..These data suggest that PGIS upregulation is part of the adaptive response of vascular cells to hypoxic stress and could play a role in counteracting the deleterious effect of inflammatory stimuli...
- Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1)M Ii
First Department of Internal Medicine, Osaka Medical College, 2 7 Daigaku machi, Takatsuki, 569 8686, Osaka, Japan
Cardiovasc Res 52:500-8. 2001..Furthermore, we determined its anti-atherosclerotic effects in cultured smooth muscle cells (SMCs)...
- Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodelingJun ichi Kawabe
Department of Pharmacology, Asahikawa Medical College, Midorigaoka Higashi 2 1 1 1, Asahikawa 078 8510, Japan
Arterioscler Thromb Vasc Biol 30:464-70. 2010..We evaluated whether prostaglandin I(2) plays a role in the regulation of the function of EPCs to limit vascular remodeling...
- Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptorKen Shinmura
Department of Internal Medicine, Keio University School of Medicine, Shinanomachi, Tokyo, Japan
Am J Physiol Heart Circ Physiol 288:H2093-101. 2005..The data also indicate that activation of EP3 receptors primes the opening of mitochondrial K(ATP) channels and that this mechanism is essential for EP3-dependent protection...
- Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertensionKelly M Chin
Department of Internal Medicine, University of Texas Southwestern Pulmonary Hypertension Program, Dallas, TX 75235 9254, USA
Chest 135:130-6. 2009..Thrombocytopenia develops in some patients with advanced pulmonary arterial hypertension (PAH) while receiving IV epoprostenol therapy...
- Segmental cerebral vasoconstriction: successful treatment of secondary cerebral ischaemia with intravenous prostacyclinPer Olof Grände
Department of Anaesthesiology and Intensive Care, Lund University and Lund University Hospital, Lund, Sweden
Cephalalgia 30:890-5. 2010..Although not fully compatible, our case had several clinical characteristics and radiological findings reminiscent of those of the 'segmental reversible vasoconstriction syndrome', sometimes called the Call-Fleming syndrome...
- Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertensionHashimoto Katsushi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Japan
Circ J 68:227-31. 2004..Monocyte chemoattractant protein-1 (MCP-1) is recognized as a potent chemotactic and activating factor for monocytes and leukocytes, but its significance in PPH is unclear...
- Transesophageal echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenolAndre Martineau
Department of Anesthesiology, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec, H1T 1C8 Canada
Anesth Analg 96:962-4, table of contents. 2003..Transesophageal echocardiography was useful in the diagnosis of CO2 embolism and to assess response to inhaled epoprostenol.
- Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteersKevin Laliberte
United Therapeutics Corporation, Research Triangle Park, North Carolina 27709, USA
J Cardiovasc Pharmacol 44:209-14. 2004..4 and 4.6 hours following intravenous and subcutaneous administration, respectively. Based on these findings it was concluded that intravenously and subcutaneously administered treprostinil are bioequivalent at steady state...
- Impact of stable PGI₂ analog iloprost on early graft viability after liver transplantation: a pilot studyErik Bärthel
Department of General, Visceral and Vascular Surgery, Friedrich Schiller University, Jena, Germany
Clin Transplant 26:E38-47. 2012..The aim of this study was to analyze the effect of the continuously administered prostaglandin I(2) analog iloprost on allograft function after LT...
- Prostacyclin in the intensive care settingD Dunbar Ivy
Department of Pediatrics, University of Colorado Denver School of Medicine, The Children s Hospital, Aurora, CO, USA
Pediatr Crit Care Med 11:S41-5. 2010..Three prostanoids have been developed to treat PAH: epoprostenol, treprostinil, and iloprost...
- Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generationK K Meja
Imperial College School of Medicine, National Heart and Lung Institute, London
Br J Pharmacol 122:149-57. 1997..Given the pharmacological behaviour of butaprost, AH 6809 and AH 23848B in these cells, we propose that multiple (EP2- and/or EP-4- and/or i.p.) or novel EP-receptors mediate the inhibitory effect of PGE2 on TNF alpha generation...
- Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluationY F Chen
Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, University of Birmingham, UK
Health Technol Assess 13:1-320. 2009To investigate the clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of adults with pulmonary arterial hypertension (PAH) within their licensed indications.
- Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritisAnne Marie Pulichino
Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
J Pharmacol Exp Ther 319:1043-50. 2006..The results also suggest that the inhibition of PGI(2) synthesis by NSAIDs and COX-2 inhibitors, in addition to that of PGE(2), contributes to their efficacy in treating the signs of arthritis...
- Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome studyMagnus Olivecrona
Department of Neurosurgery, Umea University Hospital, Umea, Sweden
J Neurotrauma 26:1251-62. 2009..This study is a prospective consecutive double-blinded randomized study on the effect of PGI(2) versus placebo in severe traumatic brain injury (sTBI). All patients with sTBI were eligible...
- Prostacyclin signaling regulates circulating ghrelin during acute inflammationLisa D Madison
Department of Pediatrics Neuroscience Graduate Program, Oregon Health and Science University, Portland, Oregon, USA
J Endocrinol 196:263-73. 2008..These data provide further support for the potential role of ghrelin as a therapeutic agent in acute and chronic inflammatory diseases...
- Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenolKarl P Kuhn
Center for Lung Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2650, USA
Am J Respir Crit Care Med 167:580-6. 2003b>Epoprostenol has markedly improved the treatment of pulmonary arterial hypertension, although predictors of outcome with epoprostenol are not well characterized...
- Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertensionStuart Rich
Department of Medicine, University of Chicago, Section of Cardiology, 5841 S Maryland Ave, Ste LO 8 MC 5403, Chicago, IL 60637, USA
Chest 138:1234-9. 2010..We report the autopsy findings from a patient with idiopathic PAH treated with epoprostenol successfully for 18 years. The patient died of colon cancer...
- Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenolMinako Oikawa
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
J Am Coll Cardiol 45:1849-55. 2005..ventricular (RV) [(18)F]fluorodeoxyglucose (FDG) accumulation is increased in patients with pulmonary hypertension using gated positron emission tomography (PET) and whether RV FDG accumulation changes after therapy with epoprostenol.
- Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smokeS Patrick Nana-Sinkam
The Ohio State University, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 201 Davis Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210, USA
Am J Respir Crit Care Med 175:676-85. 2007..Prostacyclin (PGI(2)) is a major product of the cyclooxygenase pathway with potent vasodilatory and antimitogenic properties and may be relevant to endothelial dysfunction in COPD...
- cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medullaT Namba
Department of Pharmacology, Faculty of Medicine, Kyoto University, Japan
J Biol Chem 269:9986-92. 1994..Northern blot analysis revealed that the mRNA is expressed most abundantly in thymus, followed by spleen, heart, and lung. In situ hybridization of thymus showed that it is expressed exclusively in medulla and not in cortex...
- Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosisH Olschewski
Depatment of Internal Medicine II, Justus Liebig University, Giessen, Germany
Am J Respir Crit Care Med 160:600-7. 1999..Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis...
- Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expressionDevashish Kothapalli
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6084, USA
Mol Pharmacol 64:249-58. 2003..We conclude that PGI2 inhibits proliferation of aortic smooth muscle cells by coordinately blocking CRE- and pocket protein-dependent cyclin A gene expression...
- Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cellsWeisong Zhou
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 2650, USA
J Leukoc Biol 81:809-17. 2007..These data indicate that PGI(2) analogs have an immune-suppressive effect on previously activated and differentiated CD4 T cells in vitro and suggest that PGI(2) may have a similar function in vivo...
- RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonistsKeith R Bley
Roche Palo Alto, Palo Alto, CA 94304, USA
Br J Pharmacol 147:335-45. 2006..These data suggest that RO1138452 and RO3244794 are potent and selective antagonists for both human and rat IP receptors and that they possess analgesic and anti-inflammatory potential...
- Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illnessKoichi Hashimoto
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
J Virol 78:10303-9. 2004..These results suggest that signaling through IP has antiviral effects while protecting against RSV-induced illness and that PGI(2) is a potential therapeutic target in the treatment of RSV...
- Survival in primary pulmonary hypertension: the impact of epoprostenol therapyVallerie V McLaughlin
Rush Presbyterian St Luke s Medical Center, Department of Medicine, Section of Cardiology, Chicago, Ill 60612, USA
Circulation 106:1477-82. 2002..8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration-approved therapy for PPH...
- Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertensionMardi Gomberg-Maitland
Pulmonary Hypertension Center, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 2016, Chicago, IL 60637, USA
Am J Respir Crit Care Med 172:1586-9. 2005Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension...
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trialGerald Simonneau
Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
Ann Intern Med 149:521-30. 2008Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.
- Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in plateletsM W Radomski
Wellcome Research Laboratories, Beckenham, Kent
Br J Pharmacol 92:181-7. 1987..6 It is likely that the inhibitory effect of NO on platelets represents the action of endogenous EDRF and therefore this substance, together with prostacyclin, is a regulator of platelet-vessel wall interactions...
- Altered pain perception and inflammatory response in mice lacking prostacyclin receptorT Murata
Department of Pharmacology, Faculty of Medicine, Kyoto University, Sakyo, Japan
Nature 388:678-82. 1997..Our results establish that prostacyclin is an antithrombotic agent in vivo and provide evidence for its role as a mediator of inflammation and pain...
- Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cellsHeng Lin
Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan
J Cell Physiol 214:434-41. 2008..Taken together, the results suggest that the causal relationship between PPARdelta and iNOS contributes to the vasoprotective action of beraprost in RASMCs...
- Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertensionEmilia Falcetti
Department of Medicine, UCL, London, United Kingdom
Am J Respir Crit Care Med 182:1161-70. 2010....
- A novel pathway of prostacyclin signaling-hanging out with nuclear receptorsHyunjung Lim
Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri 63110, USA
Endocrinology 143:3207-10. 2002..This review attempts to cover recent developments in nuclear actions of PGI(2) in diverse biological functions...
- Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in miceKoichi Nagao
Department of Pharmacology, Gifu Pharmaceutical University, Japan
Am J Respir Cell Mol Biol 29:314-20. 2003....
- Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatmentKimberly A Fisher
Pulmonary Center, Boston University School of Medicine, Boston, MA, USA
Chest 130:1481-8. 2006..Pulmonary hypertension is a known complication of sarcoidosis and is associated with increased mortality. Little is known about the outcome of sarcoidosis-associated pulmonary hypertension, including response to treatment...
- Augmentation of allergic inflammation in prostanoid IP receptor deficient miceYoshimasa Takahashi
Department of Pharmacology, Gifu Pharmaceutical University, 5 6 1 Mitahora Higashi, Gifu 502 8585, Japan
Br J Pharmacol 137:315-22. 2002..These findings suggest a regulatory role of PGI(2) in allergic inflammation...
- Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertensionRonald J Oudiz
Division of Cardiology, Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
Chest 126:90-4. 2004..the incidence of catheter-related infection in patients with pulmonary arterial hypertension (PAH) receiving epoprostenol (EPO), and to note an etiologic role for Micrococcus spp, which is rarely reported as a pathogen in the medical ..
- Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluentsKenneth R Phares
United Therapeutics Corporation, 68 T W Alexander Drive, Research Triangle Park, NC 27709, USA
Am J Health Syst Pharm 60:916-22. 2003..Treprostinil sodium 0.004 mg/mL in sterile water and 0.9% sodium chloride for injection and 0.02 mg/mL in 5% dextrose injection was also stable under the same conditions. None of the solutions showed signs of microbial growth...
- Coxibs and cardiovascular diseaseGarret A Fitzgerald
Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA
N Engl J Med 351:1709-11. 2004
- Effect of enhanced prostacyclin synthesis by adenovirus-mediated transfer on lipopolysaccharide stimulation in neuron-glia culturesMay Jywan Tsai
Neural Regeneration Laboratory, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Shih Pai Road, Sec 2, Taipei, Taiwan 11217
Ann N Y Acad Sci 1042:338-48. 2005..Taken together, enhanced prostacyclin synthesis in neuron-glial cultures reduced microglia number and suppressed LPS stimulation...
- Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogsZeenat Safdar
Baylor College of Medicine, 6620 Main Street, Suite 11B 09, Houston, TX 77030, USA
Respir Med 105:818-27. 2011..This review discusses the pharmacology, clinical effects, and routes of administration of prostacyclin and prostaglandin analogs, emphasizing the advantages and disadvantages of each from the clinical perspective...
- Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprostPaola Castagnino
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6084, United States
Prostaglandins Other Lipid Mediat 93:20-4. 2010..We conclude that stable PGI(2) mimetics may be highly specific inhibitors of p27(kip1)-dependent VSMC proliferation after vascular injury...
- Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineursT Wienecke
Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Danish Headache Centre, Glostrup, Copenhagen, Denmark
Cephalalgia 30:179-90. 2010..We hypothesized that intravenous infusion of the stable prostacyclin analogue epoprostenol would trigger migraine-like attacks in migraineurs...
- Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodiumMaho Watanabe
Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan ku, Fukuoka, Japan
Am J Nephrol 30:1-11. 2009..The present study aimed to examine whether the prostaglandin I(2) analog beraprost sodium (BPS) ameliorates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rat...
- Treprostinil for the treatment of pulmonary hypertensionNika Skoro-Sajer
Medical University of Vienna, Division of Cardiology, Department of Internal Medicine II, Waehringer Guertel 18 20, 1090 Vienna, Austria
Expert Opin Pharmacother 9:1415-20. 2008....
- Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertensionSusanna Desole
Pneumology University Specialized Center for Pulmonary Hypertension Innsbruck, Internal Medicine I, Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria
Heart Lung 41:599-605. 2012..However, intravenous prostacyclin treatment involves several limitations, because the available battery-driven pump systems carry the risk of line infections, catheter-related embolisms, thrombosis, and delivery system malfunctions...
- Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurementsP O Grande
Department of Anaesthesia and Intensive Care, University Hospital of Lund, Sweden
Acta Anaesthesiol Scand 44:886-94. 2000....
- Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analoguesC H Hung
Dept of Paediatrics, Kaohsiung Medical University Hospital, No 100, Tz You 1st Road, Kaohsiung 807, Taiwan
Eur Respir J 33:405-10. 2009....
- COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosisAlysia Kern Lovgren
Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 27599, USA
Am J Physiol Lung Cell Mol Physiol 291:L144-56. 2006..If such protection is observed, investigation of these agents as a novel therapeutic approach to pulmonary fibrosis in humans may be warranted...
- A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heartKazuto Nakamura
Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Hongo, Bunkyo ku, Tokyo, Japan
Clin Sci (Lond) 112:607-16. 2007..In conclusion, our results indicate that ONO-1301 up-regulated endogenous growth factors and promoted angiogenesis in response to acute ischaemia. Therefore ONO-1301 might have a therapeutic potential in treating ischaemic diseases...
- Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertensionRobert C Bourge
University of Alabama at Birmingham, Birmingham, AL 35294, USA
Cardiovasc Ther 31:38-44. 2013....
- Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulationJun Yang Liou
Vascular Biology Research Center, Brown Foundation Institute of Molecular Medicine, Houston, TX 77030 1503, USA
Arterioscler Thromb Vasc Biol 26:1481-7. 2006..To determine the role of prostacyclin (PGI2) in protecting endothelial cells (ECs) from apoptosis and elucidate the protective mechanism...
- Endothelial mediators of the acetylcholine-induced relaxation of the rat femoral arteryHok Sum Leung
Li Ka Shing Institute of Health Sciences and Department of Physiology, Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China
Vascul Pharmacol 44:299-308. 2006..Thus, the eNOS-dependent H2O2 is likely to be the third mediator of acetylcholine-mediated relaxations in rat femoral arteries...
- Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole bloodChiara Tamburrelli
Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, Center for High Technology Research and Education in Biomedical Sciences John Paul II, Catholic University, Campobasso, Italy
Thromb Res 128:446-51. 2011..b>Epoprostenol is a synthetic salt of PGI2 (prostacyclin) clinically used in pulmonary hypertension and transplantation as a ..
- The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support personsHeather Hall
Jewish General Hospital, School of Nursing, McGill University, Montreal, Quebec, Canada
Heart Lung 41:35-43. 2012Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH)...
- Cytochrome P-450 metabolites but not NO, PGI2, and H2O2 contribute to ACh-induced hyperpolarization of pressurized canine coronary microvesselsMitsuaki Tanaka
Department of Comprehensive Medicine, Tohoku University School of Medicine, 1 1 Seiryo machi, Aobaku, Sendai 980 8574, Japan
Am J Physiol Heart Circ Physiol 285:H1939-48. 2003....
- Prostacyclin infusion may prevent secondary damage in pericontusional brain tissuePeter Reinstrup
Department of Intensive and Perioperative Care, Lund University Hospital, Lund, Sweden
Neurocrit Care 14:441-6. 2011..When biochemical signs of cerebral ischemia progressed, i.v. infusion of prostacyclin was started...
- Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulationChang Hung Kuo
Department of Pediatrics, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan, Republic of China
J Mol Med (Berl) 89:29-41. 2011..PGI(2) analogues may therefore increase Th2 recruitment and inflammation...
- Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric functionKeith Morrison
Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
J Pharmacol Exp Ther 335:249-55. 2010..The high functional selectivity of selexipag and ACT-333679 for the IP receptor precludes a stimulatory action on gastric smooth muscle and may help minimize gastric side effects such as nausea and vomiting...
- Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteersS Karl Gotzkowsky
United Therapeutics Corporation, 55 T W Alexander Drive, PO Box 14186, Research Triangle Park, NC 27709, USA
J Clin Pharmacol 50:829-34. 2010..06) and 1.03 (0.94, 1.13). In conclusion, because the GMR and 90% CI are within the equivalence interval of 0.8 to 1.25, co-administration of oral treprostinil and bosentan did not result in a pharmacokinetic interaction for either agent...
- New insights into the intracellular mechanisms by which PGI2 analogues elicit vascular relaxation: cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channelYoshio Tanaka
Department of Chemical Pharmacology, Toho University School of Pharmaceutical Sciences, 2 2 1 Miyama, Funabashi City, Chiba 274 8510, Japan
Curr Med Chem Cardiovasc Hematol Agents 2:257-65. 2004..Our recent work demonstrates a functional tight coupling between IPR and MaxiK channel through a cAMP-independent, G(s)-protein mediated mechanism(s) in vascular smooth muscle...
- Retinoic acid induces PGI synthase expression in human endothelial cellsMercedes Camacho
Angiology, Vascular Biology, and Inflammation Laboratory of the Institute of Research, Hospital Santa Creu i Sant Pau, Barcelona, Spain
J Lipid Res 49:1707-14. 2008..These results reinforce the concept that RA could be beneficial for patients with cardiovascular risk...
- Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathwayKoichiro Kamio
University of Nebraska Medical Center, 985885 Nebraska Medical Center, Omaha, NE 68198 5885, USA
Am J Respir Cell Mol Biol 37:113-20. 2007..The ability of prostacyclin to modulate fibroblast function suggests that prostacyclin can contribute to tissue remodeling...
- Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclinCornelia Lundblad
Department of Anesthesiology and Intensive Care, University of Lund and Lund University Hospital, Lund, Sweden
J Cereb Blood Flow Metab 28:367-76. 2008..We conclude that the prostacyclin IP receptor is beneficial for neuron survival after brain trauma in mice, an effect that may be mediated by improved cortical perfusion...
- PPAR gamma Agonists for Lung Cancer ChemopreventionRobert Keith; Fiscal Year: 2013..Our results will lead to a better understanding of the early stages of lung cancer and may lead to future human chemoprevention trials. ..
- Endothelial Lipoxygenase Metabolites and Vascular ToneWILLIAM BRYSON CAMPBELL; Fiscal Year: 2013..These studies will identify two new mechanisms of action for the endothelium-derived relaxing factor 11,12,15-THETA and provide a new therapeutic approach to enhancing endothelial function. ..
- Mechanobiology of Vascular Remodeling in Pulmonary Arterial HypertensionLAURA ELIZABETH FREDENBURGH; Fiscal Year: 2013....
- Arterial Stiffness in the Pathogenesis of Human Pulmonary Arterial HypertensionLAURA ELIZABETH FREDENBURGH; Fiscal Year: 2013....
- Anti-PAH Drugs in Inhalable Nanoparticles for Sustained Pulmonary VasodilationFakhrul Ahsan; Fiscal Year: 2010..collapse due to interruption of infusion are the potentially serious complications of PAH therapy with epoprostenol and treprostinil...
- The Role of PGI2 in Allergic InflammationRay Stokes Peebles; Fiscal Year: 2013..Therefore, defining the role of PGI2 and its cellular receptor in allergic inflammation in vivo might result in novel targets for drug development in this important disease. ..
- THE TREATMENT OF PULMONARY HYPERTENSIONJames Pachence; Fiscal Year: 2000..General vasodilators such as hydralazine and the prostacyclin analogue epoprostenol have been used, but are only marginally effective...
- PGI & TXA SYNTHASES--MEMBRANE ANCHOR STRUCTURE/FUNCTIONKe He Ruan; Fiscal Year: 1999..Comparisons can then be made between the membrane anchor structure of these two eicosanoid-forming P450s and the anchor structures of other microsomal P450s. ..
- ROLE OF C-AMP IN RENIN RELEASEWINFRED MAGEE; Fiscal Year: 1990..Data on renin release and cyclic adenosine monophosphate production as determined by radioimmunoassay on a cell culture system enriched in juxtaglomerular cells will be evaluated...
- Mentored Patient-Oriented Research Career Development AwIVAN ROBBINS; Fiscal Year: 2004..Over the past decade, intravenous epoprostenol, the synthetic analogue of prostacyclin, has emerged as the most effective treatment of PPH...
- REGULATION OF ENDOTHELIAL CELL PHOSPHOLIPASES A2 AND CThomas Martin; Fiscal Year: 1990..Specific antisera to these proteins are investigated for their ability to reverse or attenuate glucocorticoid effects...
- Nitric Oxide/Carbon Monoxide in Pulmonary HypertentionRaed Dweik; Fiscal Year: 2006..As an extension of this hypothesis, we also propose that effective therapies such as epoprostenol, may act in part by increasing NO levels in PPH...
- ROLE OF ENDOTHELIN IN PERINATAL PULMONARY VASOREGULATIONDAVID IVY; Fiscal Year: 2002..Research presentations along with graduate level courses in molecular biology, and the clinical ambiance of the Univ of CO SOM in the area of pulmonary hypertension enhance career development. ..
- Prostaglandin I synthase, Thromboxane A synthase & Prostaglandin E synthaseKe He Ruan; Fiscal Year: 2009....
- STRUCTURE & FUNCTION RELATIONSHIP: PROSTANOID RECEPTORSKe He Ruan; Fiscal Year: 2008..Determine the solution conformation of segments comprising the intracellular domains. ..
- RELATIVE ARGININE DEFICIENCY IN PULMONARY HYPERTENSIONDavid Badesch; Fiscal Year: 2004..abstract_text> ..
- Cardiopulmonary Exercise Testing: Pulmonary HypertensionRonald Oudiz; Fiscal Year: 2007.._l.Center. PHS 398/2590(Rev.05/01) Page _, LJ ContinuationFormatPage NumberpagesconsecutivelyatthebottomthroughoutheapplicationD. o no_u_stesuffixesuchas3a, 3b. ..
- Oxidative Modifications in AtherogenesisGarret FitzGerald; Fiscal Year: 2006..abstract_text> ..
- Protective Efficacy of Mg-Supplementation Against NRTI-induced Cardiac ToxicityIVAN MAK; Fiscal Year: 2007..This proposed exploratory effort may reveal a potential usefulness of Mg-supplements as an effective, yet relatively inexpensive adjunct therapy to lessen NRTI-related cardiovascular toxicity. ..
- ACTION - A CHF Trial Investigating Outcomes of ExerciseCHRISTOPHER O CONNOR; Fiscal Year: 2008..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
- PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DX-IIVictor Tapson; Fiscal Year: 2003..abstract_text> ..
- GENETIC DETERMINATION OF ALLOGRAFT VASCULOPATHYRaymond Benza; Fiscal Year: 2002..If his faculty mentor were to leave the institution, a new mentor will be appointed and his continued development toward becoming a independent physician scientist supported and encouraged. ..
- Pharmacogenomics in Pulmonary Arterial HypertensionRaymond Benza; Fiscal Year: 2008..PAH = pulmonary arterial hypertension PA = pulmonary artery PPH = primary pulmonary hypertension ..
- Nicotine and Chronic Kidney DiseaseEdgar A Jaimes; Fiscal Year: 2010..We will use a variety of state of the art techniques to assess the mechanisms by which nicotine induces renal injury. ..
- Oxidative stress, Homocysteine and Alzheimer's DiseaseDomenico Pratico; Fiscal Year: 2008..These studies will be a necessary basis before prevention studies aimed to reduce Hcy levels are initiated in patients at risk for AD. ..
- Regulation of Prostacyclin in Pulmonary HypertensionSERGE NANA SINKAM; Fiscal Year: 2008..abstract_text> ..
- EDHF in the Cerebral CirculationROBERT BRYAN; Fiscal Year: 2009..Furthermore, we anticipate that new information regarding tandem pore domain potassium channels will be a big step in the understanding of cerebral circulatory control. ..
- PLACENTAL FUNCTION IN PREECLAMPSIAYuping Wang; Fiscal Year: 2009..Results obtained from the proposed work should enhance our knowledge and establish a direct link of placental TC activity and EC dysfunction in PE. ..
- Mast Cell-Induced Inflammation in Vascular DiseaseKottarappat N Dileepan; Fiscal Year: 2010..abstract_text> ..
- Proatherogenic properties of platelet fator 4Bruce S Sachais; Fiscal Year: 2010..into the role of PF4, the most abundant protein released by activated platelets, on the development of atherosclerosis, delineate the pathways by which this occurs in vivo, and suggest potential methods to intervene in atherogenesis ..
- ENDOTHELIAL BARRIER FUNCTION IN PREECLAMPSIAYuping Wang; Fiscal Year: 2010..The influence of CLP on placental sFlt-1 will be studied. Results obtained from the proposed work should enhance current knowledge of the role of the placenta and EC dysfunction in the pathogenesis of PE. ..
- Tetrahydrobiopterin: Regulator of Endothelial FunctionZVONIMIR KATUSIC; Fiscal Year: 2009..This information may help to develop new strategies in prevention and treatment of endothelial dysfunction. . ..
- Role of ANG II in Maintaining Vascular Relaxation in Dahl S RatsJulian H Lombard; Fiscal Year: 2010..abstract_text> ..
- EICOSANOIDS, VASCULAR TONE AND BLOOD PRESSUREWILLIAM BRYSON CAMPBELL; Fiscal Year: 2010..These studies will test the hypothesis that endogenous LO metabolites are important regulators of vascular tone and blood pressure in mice. ..
- 8th World Congress for MicrocirculationJULIAN LOMBARD; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Mechanochemical regulation of endothelial permeabilityKonstantin Birukov; Fiscal Year: 2007....
- CEREBAL ARTERIAL ADVENTITIA AND VASOSPASMZVONIMIR KATUSIC; Fiscal Year: 2001..Our studies will also expand the knowledge base concerning the vascular biology of adventitia, and its role as a target for transfer and expression of therapeutically beneficial recombinant proteins. ..
- Nitric Oxide-Superoxide in Lipid Induced Vascular DiseasZVONIMIR KATUSIC; Fiscal Year: 2005....
- Nitric Oxide Regulation of Adrenal SteroidogenesisWilliam Campbell; Fiscal Year: 2004..4) We will determine the role of endothelial NO in regulating steroidogenesis and adrenal blood flow in the in situ perfused adrenal gland and in vivo in anesthetized rats. ..
- Role of Erythrocytes in Circulatory ControlRandy Sprague; Fiscal Year: 2004..abstract_text> ..
- Drugs targeting intact lipoprotein receptorsBRUCE SACHAIS; Fiscal Year: 2004..Specific Aim 2: Create and validate biosensor-based analysis of LDL-R lipoparticles. In this aim, we will use LDL-R lipoparticles on the optical biosensor platform with the goal of measuring ligand-binding kinetics. ..
- CARDIAC VALVE CALCIFICATIONEmile Mohler; Fiscal Year: 2003..2. To investigate mechanisms of valve calcification using a cell culture model of calcification. 3. To examine therapeutic strategies to inhibit valve calcification with a bisphosphonate in cell culture. ..
- CYTOCHROME P450 EICOSANOIDS AND PULMONARY HEMODYNAMICSAlan Stephenson; Fiscal Year: 2002..abstract_text> ..
- PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSIONKaren Fagan; Fiscal Year: 2002..Improved understanding of these endogenous vasoregulatory substances, their interactions with one another, and the effect of modest hypoxia in vivo are the major goals of this proposal and may lead to new therapeutic options. ..
- MECHANISMS OF PROSTAGLANDIN INDUCED INTESTINAL REPAIRAnthony Blikslager; Fiscal Year: 2002..These experiments will provide insight into the signaling pathways and mechanisms by which prostaglandins trigger repair of acutely-injured intestinal epithelium. ..
- MECHANISMS OF ALTERED VASOREACTIVITY IN SCLERODERMANICHOLAS FLAVAHAN; Fiscal Year: 2002..These studies should increase our understanding of the SSc disease process and may provide a scientific basis for therapeutic intervention. ..
- Discovery of biomarkers of pulmonary hypertensionRubin Tuder; Fiscal Year: 2005..abstract_text> ..
- The Erythrocyte: a Regulator of Microvascular PerfusionMary Ellsworth; Fiscal Year: 2005..abstract_text> ..
- Il-6 type cytokine protection from hyperoxic lung injuryAaron Waxman; Fiscal Year: 2007..abstract_text> ..
- Neurohormonal Activation in Pulmonary HypertensionSteven Kawut; Fiscal Year: 2005..We will formulate prediction rules using neurohormone levels and clinical variables to improve prognostication and management in this disease. ..
- Effects of BMPRII Mutations in Pulmonary HypertensionKaren Fagan; Fiscal Year: 2006..We will have also tested the role of four pulmonary cell types, smooth muscle, endothelium, airway epithelium and macrophages in the link between BMPR2 and pulmonary hypertension. ..
- Genetics of Pulmonary Hypertension in MiceKaren Fagan; Fiscal Year: 2006..abstract_text> ..
- The Role of Central Melanocortins in CachexiaDaniel Marks; Fiscal Year: 2006..Ultimately, this work may lead to investigation of drug therapy for this widespread medical problem. ..
- Regulation of Nuclear Import/Export of 5-LipoxygenaseThomas Brock; Fiscal Year: 2006..This foundation can then be used to elucidate the ways these factors can change and give rise to the disease states that arise from abnormal 5-LO localization and LT synthesis. ..
- Pulmonary Arterial Hypertension: Avian Model of Complex Vascular Lesion DevelopmeROBERT WIDEMAN; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Cognitive dysfunction in neuropsychiatric-SLEMichael Lockshin; Fiscal Year: 2002..Successful completion of this research will redefine the pathogenesis of cognitive dysfunction and suggest therapeutic targets for intervention...
- LC-MS/MS for Biomedical ResearchWilliam Campbell; Fiscal Year: 2004..About 75-80% of instrument time will be available to these participants and the remaining time will be available to other investigators at the College. ..
- ETHANOL SENSITIVITY OF NATIVE AND CLONED NMDA RECEPTORSJohn Woodward; Fiscal Year: 2009..Aim 3 will express ethanol-insensitive receptors identified in Aims 1 and 2 in neurons in vitro and in vivo to address which effects of ethanol are mediated by inhibition of NMDA receptors. ..
- The neurobiology of 12/15 lipoxygenaseDomenico Pratico; Fiscal Year: 2007..Such data are clinically relevant and should provide important clues to the potential use of specific 12/15LO inhibitors as novel therapeutic agents for preventing or limiting the evolution and/or progression of AD. ..
- NO& Epithelial Repair in CryptosporidiosisJody Gookin; Fiscal Year: 2006..abstract_text> ..
- Mechanisms of Vascular Dysfunction in Vibration InjuryNICHOLAS FLAVAHAN; Fiscal Year: 2009..2 will determine mechanisms underlyingthe vibration-induced increase in cold sensitivity of cutaneous arteries;and Aim 3 will determine the effects of vibration on endothelial cell function and vascular structure ..
- Redox Regulation of Arteriole FunctionNICHOLAS FLAVAHAN; Fiscal Year: 2005..Experiments will assess the stimuli responsible for ROS production, the mechanisms underlying ROS-induced changes in vasoconstriction and the regulation of this signaling pathway in hypertension. ..